1286 results for "MDMA"
Can psychedelics have a role in psychiatry once again?
The British Journal of Psychiatry – June 01, 2005
Summary
Ancient wisdom meets modern science: Hallucinogens like Mescaline (a Phenethylamine), Psilocybin, and Lysergic acid derivatives such as Lysergic acid diethylamide (LSD) have been used for thousands of years. Contemporary Psychology and Psychedelics and Drug Studies now investigate their profound Neurotransmitter Receptor Influence on Behavior, with MDMA showing promise for Treatment of Major Depression. This field explores their therapeutic potential and mechanisms.
Abstract
Psychedelic or hallucinogenic drugs such as lysergic acid diethylamide (LSD), 3, 4, 5-trimethoxy-β-phenethylamine (mescaline), psilocybin, 3, 4-met...
The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review
Frontiers in Psychiatry – November 20, 2017
Summary
Hallucinogen-persisting perception disorder (HPPD), a syndrome causing prolonged visual disturbances reminiscent of acute drug effects, was only established as a formal diagnosis in 2000, despite being described in 1954. This condition, explored through MEDLINE and other databases, is linked to a broad range of substances including Lysergic acid diethylamide (LSD), psilocybin, mescaline, and MDMA (Ecstasy). Its psychopathology primarily involves visual anomalies, though depressive symptoms can co-occur. Understanding HPPD's neural basis and risk factors remains a critical area in psychology and psychiatry, informing clinical psychology and medicine.
Abstract
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acut...
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
Journal of Substance Use – July 30, 2010
Summary
Over 81% of hallucinogen users reported a profound spiritual experience, with over 90% linking classic psychedelics like Psilocybin and Lysergic acid diethylamide to accessing the unconscious mind. A survey of over 600 individuals revealed users perceive less harm from these substances compared to MDMA or Cannabis. Many reported therapeutic benefits for Addiction and mood disorders, suggesting a promising avenue for Psychiatry and Psychology. This highlights the potential for Neurotransmitter Receptor Influence on Behavior, suggesting deeper inquiry in Psychedelics and Drug Studies, extending beyond Cannabis and Cannabinoid Research.
Abstract
This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were...
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
Behavioural Pharmacology – March 01, 2004
Summary
Though not reliably sought, 3 out of 4 rhesus monkeys with prior MDMA self-administration experience did self-administer the hallucinogens mescaline, psilocybin, or DMT in some sessions. These animals responded between 0.75 and 3.0 times per second, appearing intoxicated. In psychology and pharmacology, comprehensive behavioral observations, like scratching, are crucial. This suggests these psychedelics may have weak reinforcing effects, unlike saline, impacting future medicine and drug studies. Forensic toxicology could further explore neurotransmitter receptor influence on behavior.
Abstract
Relatively few studies have assessed the reinforcing effects of hallucinogenic compounds, and no such studies have attempted to engender contingent...
Counselors’ attitudes toward psychedelics and their use in therapy
Journal of Counseling & Development – March 19, 2022
Summary
The "psychedelic renaissance" heralds a new era in mental healthcare, with MDMA and psilocybin nearing FDA approval for therapeutic use. This profound shift is reshaping Psychiatry and Clinical Psychology, yet the counseling profession has been slow to engage. A recent poll of psychotherapists revealed mixed attitudes toward hallucinogen use, though support was strong for medically supervised applications. Crucially, most counselors recognized the immense potential of these Psychedelics in therapy, underscoring a burgeoning interest within Psychology and the broader realm of Drug Studies.
Abstract
Abstract The ‘‘psychedelic renaissance’’ is generating new evidence for psychedelics’ potential to treat numerous mental and substance use disorder...
Drugs of Abuse Monitoring in Blood for Control of Driving Under the Influence of Drugs
Therapeutic Drug Monitoring – April 01, 2002
Summary
Driving under the influence is a critical public safety issue; forensic toxicology is crucial for detection. A comprehensive review details analytical chemistry procedures for over 20 drugs in blood, vital for identifying impaired drivers. Covered are stimulants like Amphetamine, Methamphetamine, MDMA; opiates such as Codeine, Morphine, Methadone; and hallucinogens including Lysergic acid diethylamide, Psilocybin. Benzoylecgonine, Gamma hydroxybutyrate, and various cannabinoids, including synthetic cannabinoids and designer drugs, are also addressed. Chromatography methods underpin this pharmacology, informing poison control, medicine, and advancing drug studies.
Abstract
Driving under the influence of drugs is an issue of growing concern in the industrialized countries as a risk and a cause for road accidents. In fo...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Current Neuropharmacology – January 05, 2024
Summary
With 12 million U.S. adults impacted by traumatic stress, traditional mental health treatments often fall short. Emerging clinical psychology suggests a promising role for psychedelics in psychiatry. Hallucinogens like psilocybin and MDMA, alongside the dissociative ketamine, are being explored as potent medicine. These compounds, influencing neurotransmitter receptor behavior, offer a novel psychological intervention for mood and other mental health conditions. Psychedelics and Drug Studies are revealing how chemical synthesis and alkaloids can transform clinical care, providing new hope for those with severe mental health challenges.
Abstract
Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estima...
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Pharmacopsychiatry – May 12, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) are revolutionizing mental health treatment, offering new hope in psychiatry. These powerful hallucinogens, including MDMA, demand redefined psychological intervention. Successful integration into medicine requires careful psychopharmacology, focusing on precise dosing and comprehensive psychotherapist support. Six crucial areas, from patient screening to psychological integration, must be addressed. This contextualization of chemical synthesis and alkaloids' influence on neurotransmitter receptors is vital for future Psychology and Psychedelics and Drug Studies, ensuring safe, effective care.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs...
Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia—Relevance for Mental Diseases
Cells – July 27, 2021
Summary
Novel heteroreceptor complexes reveal a fundamental biological principle for brain signal integration, profoundly impacting neuroscience and mental health. This clarifies how atypical antipsychotics modulate D2R-5-HT2AR interactions and how antidepressants like ketamine directly bind the TrkB receptor, offering new neuropharmacology insights. This cognitive science perspective also explains therapeutic potential of psychedelics, like psilocybin, and MDMA's prosocial effects via specific receptor mechanisms involving tryptophan pathways. This biology holds significant relevance for psychology and treating brain disorders.
Abstract
The heteroreceptor complexes present a novel biological principle for signal integration. These complexes and their allosteric receptor–receptor in...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Advances in Psychedelic Medicine
OpenAlex – January 01, 2019
Summary
Psychedelics are rapidly transforming Medicine, with the U.S. government lifting its testing ban over a decade ago. Substances like Psilocybin, MDMA, and the hallucinogen Ayahuasca are now being integrated into Psychiatry and Psychology, augmenting psychotherapies for conditions like Addiction and depressive disorders. This comprehensive assessment covers clinical efficacy, safety, and ethical considerations, alongside neuroscience findings. It also explores microdosing, cannabinoid research, and training future psychotherapists in this evolving field of Psychedelics and Drug Studies.
Abstract
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psycho...
Johns Hopkins Opens Research Center on Psychedelics
Psychiatric News – October 28, 2019
Summary
Johns Hopkins has launched a $17 million Center for Psychedelic and Consciousness Research, funded for five years by private donations. This significant hub for drug studies will investigate compounds like psilocybin and MDMA for psychiatric disorders, including opioid use, PTSD, and anorexia nervosa. The Center aims to advance medicine by training future experts in psychology and psychiatry, carefully exploring psychedelics' therapeutic potential after decades of limited research. This represents a major investment in understanding these powerful substances.
Abstract
Back to table of contents Previous article Next article ProfessionalFull AccessJohns Hopkins Opens Research Center on PsychedelicsNick ZagorskiNick...
Hallucinogenic Drugs
Encyclopedia of Life Sciences – August 15, 2012
Summary
Hallucinogens, used for millennia in spiritual practices, are now central to modern psychology and pharmacology. Potent psychedelics like Lysergic acid diethylamide, Psilocybin, and Mescaline exert their powerful influence on behavior by primarily modulating serotonin neurotransmitter receptors, leading to profound perceptual and cognitive shifts. These substances, including MDMA, are popular recreational drugs, but their chemical synthesis and unique effects are driving renewed drug studies, revealing their psychotomimetic potential.
Abstract
Abstract Hallucinogens constitute one of the oldest classes of drugs used by humanity, often in the context of spiritual practices. Classic halluci...
Psychedelics for treating psychiatric disorders: Are they safe?
Current Psychiatry – December 01, 2022
Summary
Psychedelics are rapidly gaining prominence in Medicine, with some compounds designated "breakthrough therapies" by the FDA, expediting their development. Growing evidence from Drug Studies highlights their potential for treating psychiatric disorders like depression, PTSD, and substance use disorders, often alongside psychotherapy. While ketamine already treats depression and other Psychedelics anticipate FDA approval, understanding their safety profile is crucial. These substances, including psilocybin and MDMA, are generally well-tolerated, though associated with various adverse effects, signaling a significant shift in Psychiatry.
Abstract
SAM FALCONERP sychedelics are a class of substances known to produce alterations in consciousness and perception.In the last 2 decades, psychedelic...
Psychedelic Psychiatry
Advances in Clinical Medical Research and Healthcare Delivery – May 31, 2022
Summary
A remarkable Renaissance in clinical psychiatry reveals potent new treatments. Psilocybin, a powerful hallucinogen, effectively addresses depressive disorders, sometimes outperforming current 'gold standards' in mental health. MDMA, integrated with a psychotherapist's guidance in psychology-informed psychotherapy, proves a powerful tool for PTSD symptomatology. This revival in Psychedelics and Drug Studies follows decades of governmental barriers, underscoring the urgent need for improved psychiatric solutions. The potential for transforming mental well-being is significant.
Abstract
We are amidst a 'Renaissance' in the field of psychedelic psychiatry. For several decades, following a period of promising research, governmental b...
Regulatory Challenges of Integrating Psychedelics into Mental Health Sector
Psychoactives – April 22, 2025
Summary
Psychedelics are emerging as a promising method for treating mental health conditions. Substances like LSD, psilocybin, and MDMA, when administered in controlled settings with psychological support, induce profound insights. These lead to long-lasting positive changes in mood, cognition, and behavior, addressing depression, anxiety, and addiction. This revolutionizes mental health treatment. However, ethical, social, and regulatory challenges in Drug Studies require rigorous inquiry for their therapeutic use within Psychology and mental health.
Abstract
Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and r...
Funding Success of United States Federal Grant Applications Proposing to Study Therapeutic Applications of Psychedelics: A Survey Study
Psychoactives – February 05, 2025
Summary
Only 16.7% of 24 federal grant applications for therapeutic psychedelics like psilocybin and MDMA received funding, significantly below the NIH's 23.4% average. A survey of 10 leading Psychology and Psychedelics and Drug Studies researchers, identified using Library Science methods, revealed challenges in securing support. While no Chemical synthesis and alkaloids applications before 2006 were funded, recent success rates (around 20%) now align with typical NIH averages for Public administration.
Abstract
The author surveyed researchers about United States federal grant applications for therapeutic psychedelic research and their funding success. An a...
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
British Journal of Pharmacology – September 02, 2025
Summary
High-dose psilocybin, a classic hallucinogen, uniquely boosts dopamine in the brain's nucleus accumbens, a region critical for addiction. This neuroscience finding suggests psilocybin, an alkaloid, may restore dopamine homeostasis, offering a novel pharmacology mechanism for treating substance use disorders. Psychiatry and medicine are actively exploring this: 34 clinical trials are underway, primarily for alcohol addiction, investigating psychedelics like psilocybin and MDMA. This exciting development in Psychedelics and Drug Studies highlights how chemical synthesis and neurotransmitter receptor influence on behavior can advance psychology's approach to addiction.
Abstract
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depre...
Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism
Magna Scientia Advanced Research and Reviews – June 28, 2025
Summary
Trauma and substance use are profoundly underdiagnosed and undertreated in individuals with Level 1 Autism. While promising psychedelic-assisted therapies (e.g., psilocybin, MDMA, ketamine) address PTSD, and digital mental health interventions improve access, their intersection with autistic needs remains critically underexplored. This psychology review proposes a neurodevelopmentally sensitive, hybrid model. It integrates digital mental health tools with psychedelic psychological interventions to enhance mental health and trauma healing for autistic populations, addressing critical gaps in clinical psychology and psychiatry.
Abstract
Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Leve...
Data justify further research on potential of psychedelics in treating psychiatric disorders
The Brown University Psychopharmacology Update – May 06, 2020
Summary
Psilocybin and MDMA, powerful psychedelics, are showing significant promise for psychiatric medicine. A literature review concludes these drugs, including the hallucinogen psilocybin, warrant continued investigation for treating mental disorders. Both have earned "breakthrough therapy" designation from the Food and Drug Administration, accelerating their development. Understanding their profound influence on neurotransmitter receptors and human behavior is central to ongoing psychology and drug studies, aiming to integrate these compounds safely into modern psychiatry.
Abstract
Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of ...
A-118 Psychedelic Interventions for Neuropsychological Conditions
Archives of Clinical Neuropsychology – August 17, 2022
Summary
Psychedelics like MDMA and psilocybin show promise for neuropsychological conditions, beyond treating anxiety and other psychological conditions. A comprehensive review of over 800 relevant papers, drawn from 4319 identified in 1024 searches, revealed new opportunities for psychological intervention. This included potential applications for traumatic brain injury and autism spectrum disorder. While these psychedelic therapies are advancing through clinical trials in psychiatry and medicine, some contraindications exist for specific co-occurring psychological disorders, highlighting the evolving landscape of drug studies and their impact on clinical psychology.
Abstract
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depres...
The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)
European Psychiatry – March 01, 2016
Summary
Hallucinogen Persisting Perception Disorder (HPPD) causes profound, lasting visual disturbances and psychopathology, a challenging condition in psychiatry. Affecting individuals exposed to psychedelics like Lysergic acid diethylamide, psilocybin, MDMA (Ecstasy), or mescaline, its underlying mechanisms, including neurotransmitter receptor influence on behavior, remain largely unknown. Despite formal recognition in clinical psychology and medicine, a recent review of drug studies highlights this critical knowledge gap. Understanding HPPD's etiology is vital for developing effective treatments, underscoring the need for further forensic toxicology and drug analysis to unravel this complex hallucinogen-induced syndrome.
Abstract
Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, remini...
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Current Psychiatry Research and Reviews – January 21, 2024
Summary
Psychedelics, including psilocybin and MDMA, are re-emerging in Psychiatry as potent Medicine for mental illness. Decades after being classified as Schedule I hallucinogens, evidence from animal and human drug studies suggests their potential against conditions like anxiety, addiction, and treatment-resistant depression. These substances, many being alkaloids or products of chemical synthesis, are generally considered physically safe, with low risk of substance abuse or dependency. Psychology is exploring how they influence neurotransmitter receptors, offering revolutionary treatments beyond conventional psychotherapist approaches. Careful management is crucial to ensure their medical role.
Abstract
: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
Preparing for psychedelic therapies in Australia
OpenAlex – October 18, 2022
Summary
Psychedelic therapies are making a compelling comeback in Psychology and Drug Studies, poised to transform mental health care. After decades in the wilderness, clinical research is actively exploring compounds like psilocybin (from 'magic mushrooms') and MDMA ('ecstasy'). These two specific drugs, when combined with psychotherapy, demonstrate significant potential to treat various mental illnesses. This re-emergence offers new hope for effective interventions, moving these powerful tools closer to mainstream medical application.
Abstract
Psychedelic therapies have the potential to treat mental illness but there’s still a long way to go. After decades in the wilderness, psychedelic t...
Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists
Journal of Evolutionary Psychology – September 21, 2020
Summary
A single MDMA session proved profoundly meaningful for three African American female psychotherapists, addressing personal racialization and oppression. This specific compound, a synthesized alkaloid from chemical synthesis, offered mental health benefits like strength and safety. This finding in Clinical Psychology and Psychedelics and Drug Studies highlights how diverse ethnic group perspectives are vital. Effective facilitator training is key to making these natural compound pharmacology studies accessible, ensuring mental health support truly serves those facing systemic oppression.
Abstract
Abstract Psychedelic medicine is an emerging field of research and practice that examines the psychotherapeutic effects of substances classified as...
Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence
International Journal of Methods in Psychiatric Research – August 21, 2006
Summary
A compelling finding in Psychiatry: only 2% of 1186 young, recent-onset hallucinogen users (ages 12-21) exhibited features resembling a dependence syndrome. This latent class model analysis revealed 88% showed few or no such features. However, specific psychedelics matter; MDMA users had 2.4 times the estimated relative risk of rapid dependence compared to LSD users. This Psychology insight, relevant for Neurotransmitter Receptor Influence on Behavior, Psychedelics and Drug Studies, and Cannabis and Cannabinoid Research, highlights varying risks, without age or sex being factors.
Abstract
Abstract This study uses latent class methods and multiple regression to shed light on hypothesized hallucinogen dependence syndromes experienced b...
Psychedelics are Bringing a new wind to the Pharmacopoeia
Neuroscience and Neurological Surgery – February 27, 2025
Summary
A compelling shift is underway: several hundred clinical trials globally are now exploring psychedelics for mental health restoration. Substances like psilocybin from hallucinogenic mushrooms, and LSD, derived from ergot alkaloids, are key to these drug studies. From diverse geography, DMT in ayahuasca and mescaline from peyote are also being examined. MDMA, an amphetamine resulting from chemical synthesis, completes this new pharmacopoeia. This extensive research aims to revolutionize mental health treatments.
Abstract
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ...
Drug Abuse and Cardiac Problem
Medicine Today – February 10, 2014
Summary
Substance abuse, an epidemic in many nations, profoundly impacts the heart and circulation, causing significant morbidity. A review identifies 12 drugs of abuse, including Heroin, Methamphetamine, Nicotine, MDMA, Phencyclidine, and Ketamine (a hallucinogen), that induce dangerous cardiovascular changes. This pharmacology is critical for Medicine and Psychiatry. Understanding these drugs, including cannabis, is vital for forensic toxicology and drug analysis, and for comprehending their neurotransmitter receptor influence.
Abstract
Drug abuse has reached epidemic proportions in many countries including Bangladesh and threatens to overwhelm economic, social, and health care sys...
Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
OpenAlex – May 07, 2025
Summary
Australia has made a landmark decision in Medicine, becoming the first country to approve specific psychedelics for clinical use. Psychotherapists can consider MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, a significant step in Psychology. This move opens new avenues in Psychedelics and Drug Studies. Historical context and mechanisms behind these Psychotherapy Techniques and Applications suggest hope, potentially influencing perspectives on Paranormal Experiences and Beliefs for individuals in end-of-life care, where such interventions might alleviate existential distress. This development could reshape therapeutic approaches.
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic str...
FDA issues first draft guidance on psychedelic research
Mental Health Weekly – June 30, 2023
Summary
The Food and Drug Administration recently made history by issuing its first-ever draft guidance for conducting clinical trials with psychedelic drugs. This landmark move acknowledges the unique challenges in evaluating substances like psilocybin and MDMA (Ecstasy) as potential medicine. The guidance from the FDA will shape future pharmacology and drug studies, ensuring rigorous scientific standards for hallucinogens. It marks a significant step towards integrating psychedelics into mainstream medicine, paving the way for more structured clinical trial designs and potential therapeutic breakthroughs.
Abstract
Observing that designing clinical studies to evaluate the safety and effectiveness of psychedelic substances presents a number of unique challenges...
Rediscovering psychedelics
C&EN Global Enterprise – March 07, 2022
Summary
Once demonized, psychedelic compounds are now poised to revolutionize mental healthcare, offering transformative treatments for conditions like major depressive disorder and PTSD. After decades of scientific disregard, substances like psilocybin and MDMA are entering mainstream medicine. Companies are actively developing these drugs, though efforts to eliminate hallucinogenic effects through chemistry prove controversial within Psychology and Philosophy. This significant shift in Psychedelics and Drug Studies promises new avenues for addressing intractable mental illness, moving beyond past stigmas.
Abstract
Over the past decade, psychedelic compounds like psilocybin and ecstasy have emerged as potentially life-changing treatments for mental illnesses, ...
RAND: Microdosing surges as millions turned to psychedelics in 2025
Mental Health Weekly – January 23, 2026
Summary
Millions of U.S. adults are now microdosing psychedelics like psilocybin, LSD, and MDMA, signaling a major shift in drug studies. A RAND survey reveals this practice, once a niche whisper in digital communication and tech circles, has gone mainstream. Individuals are consuming sub-perceptual amounts for distinct goals, diverging from traditional full-dose use. This broad adoption suggests evolving perspectives on these substances, with implications for business and personal well-being.
Abstract
Microdosing — once a niche practice whispered about in online forums and tech circles — has firmly entered the mainstream. A new RAND survey sugges...
Stigma in drug research holding back new therapies
OpenAlex – October 10, 2022
Summary
Therapy for mental illness is undergoing a radical shift, embracing drugs once considered illicit party substances. Psychedelics like Psilocybin and MDMA, alongside medicinal Cannabis and other hallucinogens, are emerging as potential medicine in Psychiatry. This represents a significant biomedical innovation for mental health. Despite their past stigma as recreational drugs, rigorous drug studies and proper trials are crucial to validate their therapeutic role. Mental illness is a growing cause of disability, highlighting the need for these novel psychological approaches.
Abstract
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new the...
Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
The Swiss Society of Addiction Medicine (SSAM) has taken a bold stance, supporting psychedelic-assisted psychotherapy (PAT) as a viable treatment for addiction. This includes classic psychedelics like LSD and psilocybin, and ketamine, especially when conventional treatments prove inadequate. SSAM also champions an evidence-based debate on legalizing and regulating substances such as LSD, psilocybin, and MDMA in Switzerland. This covers both therapeutic and non-medical uses, aiming to minimize harm and provide access to safe, quality-controlled substances.
Abstract
Zusammenfassung: Hintergrund: Die Schweizerische Gesellschaft für Suchtmedizin (SSAM) setzt sich für die wissenschaftlich fundierte und patientenor...
Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum
Frontiers in Psychiatry – April 30, 2018
Summary
Sedative-hypnotics are most commonly mentioned with hallucinogens and stimulants in discussions about novel psychoactive substances. Analyzing 20 years of online posts, this psychology-focused work reveals complex polysubstance use patterns. For instance, synthetic hallucinogens are discussed distinctly from plant hallucinogens. Users compare designer drugs like MDMA to describe effects, offering insights for pharmacology and psychiatry. This large-scale data contributes to drug studies, providing valuable information for forensic toxicology regarding neurotransmitter receptor influence on behavior.
Abstract
Novel psychoactive substances (NPS) refer to synthetic compounds or derivatives of more widely known substances of abuse that have emerged over the...
Drug Misuse
OpenAlex – July 22, 2022
Summary
Fatal drug poisonings in England and Wales have reached an all-time high, despite overall adult drug use remaining stable for 20 years. Within this population, Cannabis is the most commonly used drug, while around a third have taken a Class A drug like MDMA. Most fatalities are associated with Heroin, underscoring the critical need for Opioid Use Disorder Treatment. Forensic Toxicology and Drug Analysis are crucial to understanding these trends across jurisdictions. Psychiatry and Medicine also play vital roles in addressing drug challenges. Cannabis and Cannabinoid Research continues to be important.
Abstract
The word ‘misuse’ as used in many Anglophone countries signifies the non-authorised use of medicines that can, in appropriate circumstances, be leg...
Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.
AIDS and behavior – January 27, 2026
Summary
Engaging in Chemsex, the intentional use of substances to enhance sexual activity, significantly increases the risk of STIs among Pre-exposure prophylaxis (PrEP) users. In Buenos Aires, 32% of 165 PrEP users reported Chemsex, often with MDMA (21%) or cocaine (14%), and 48% used multiple substances. Those engaging in Chemsex had 3.67 times higher odds of a recent STI diagnosis. These findings underscore the critical need to integrate behavioral assessments and harm reduction strategies into PrEP and sexual health policies, addressing substance use to reduce STI transmission effectively.
Abstract
Chemsex, defined as the intentional use of psychoactive substances to enhance sexual activity, has been associated with a higher frequency of sexua...
Clinical toxicology of newer recreational drugs
Clinical Toxicology – October 01, 2011
Summary
Emerging recreational drugs pose significant risks, yet clinicians lack reliable data for effective management of toxicity. A review highlights that current treatment strategies largely rely on experiences with established substances like amphetamines and MDMA. With an increasing number of users experiencing acute toxic effects, understanding the implications for intensive care medicine and forensic toxicology is crucial. Given the complexities of pharmacology and the influence of neurotransmitter receptors on behavior, comprehensive documentation of these newer drugs is essential for improved clinical outcomes.
Abstract
There are limited reliable data to guide clinicians managing patients with toxicity due to these substances. The harms associated with emerging rec...
Development of a Pencil Drawn Paper‐based Analytical Device to Detect Lysergic Acid Diethylamide (LSD)*†
Journal of Forensic Sciences – June 30, 2020
Summary
A paper-based device for detecting lysergic acid diethylamide (LSD) demonstrated impressive capabilities, with detection limits of 0.38 μmol/L and quantification limits of 1.27 μmol/L. Constructed using 8B pencils on watercolor paper, this innovative electrochemical sensor showed similar performance to a commercial carbon electrode when analyzing seized LSD samples, achieving recovery rates below 10%. The device also effectively distinguished LSD from other substances like MDMA and methamphetamine, highlighting its potential in forensic applications and the growing trend toward sustainable materials in chemical analysis.
Abstract
Abstract The need for agile and proper identification of drugs of abuse has encouraged the scientific community to improve and to develop new metho...
Trajectories of sentiment in 11,816 psychoactive narratives
Human Psychopharmacology Clinical and Experimental – December 20, 2023
Summary
Machine learning has unveiled striking correlations between sentiment and psychoactive experiences across a diverse range of 52 drugs. Analyzing 11,816 testimonials, the models identified 28 dimensions of sentiment, validated by a clinical psychiatrist. Notably, MDMA was associated with feelings of “Love,” while DMT and 5‐MeO‐DMT related to “Mystical Experiences.” The study revealed 11 significant receptor-experience factors, offering a neurobiological perspective on drug-induced feelings. This innovative approach highlights machine learning's potential in quantifying subjective experiences linked to various psychoactive substances.
Abstract
Abstract Objective Can machine learning (ML) enable data‐driven discovery of how changes in sentiment correlate with different psychoactive experie...
Language Models Learn Sentiment and Substance from 11,000 Psychoactive Experiences
OpenAlex – August 17, 2022
Summary
A striking finding reveals that MDMA is associated with "Love," while DMT and 5-MeO-DMT correlate with "Mystical Experiences." Analyzing 11,816 drug testimonials through advanced machine learning techniques, a comprehensive framework emerged, identifying 28 sentiment dimensions and linking them to 52 drugs' receptor affinities. This approach delineates 11 latent factors of drug-induced experiences, highlighting the difference between lucid and mundane states. These insights can inform therapeutic practices, potentially enhancing mental health interventions through tailored psychoactive substance applications.
Abstract
Abstract With novel hallucinogens poised to enter psychiatry, we lack a unified framework for quantifying which changes in consciousness are optima...
Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos
Revista chilena de neuro-psiquiatría – June 01, 2014
Summary
Psilocybin, a 5-HT2A receptor agonist, has shown remarkable effects, including a 50% reduction in anxiety and mood disorder symptoms among participants. It deactivates the Default Mode Network, enhancing autobiographical memory access and fostering positive emotional attention. MDMA significantly aids PTSD therapy by strengthening therapeutic alliances and reducing avoidance behaviors, linked to oxytocin release. Initial studies on ayahuasca and ketamine indicate promising results in decreasing problematic substance use, with over 40% reporting reduced cravings. These findings highlight the potential therapeutic benefits of psychedelics in mental health treatment.
Abstract
El objetivo de esta revisión consiste en exponer los principales avances en la investigación reciente con sustancias psicodélicas en las neurocienc...
Psychedelic Clinical Studies - Bibliometric Dataset
Figshare – January 01, 2021
Summary
A comprehensive bibliometric analysis of 1,200 clinical studies on psychedelics from 1965 to 2018 reveals a significant rise in publications, particularly in the last decade. Notably, psilocybin and MDMA accounted for over 60% of the articles. The data highlights trends in information retrieval and geographical distribution, emphasizing the growing interest in psychedelics within fields like computer science and data science. This analysis provides valuable insights into the evolving landscape of psychedelic research, particularly regarding chemical synthesis and reactions involving alkaloids.
Abstract
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptam...
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
Synapse – January 01, 2000
Summary
Amphetamine-type stimulants significantly increase norepinephrine (NE) release, suggesting NE's crucial role in their subjective effects. In a study involving multiple stimulants like MDMA and methamphetamine, the potency for NE release was closely linked to their ability to induce amphetamine-like effects in humans. Notably, the oral doses that produced these effects correlated with NE release rather than dopamine (DA), as evidenced by the absence of plasma prolactin reduction—a DA-mediated effect. This highlights the importance of NE in understanding stimulant behavior and pharmacology.
Abstract
A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing effects of central nervo...
Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives
Therapeutic Drug Monitoring – April 01, 2002
Summary
Amphetamines, including designer drugs like MDMA and MDA, have complex toxicokinetics that significantly impact forensic toxicology. A review of English-language publications from 1995 to 2000 analyzed over 100 studies, focusing on the metabolism of various amphetamine derivatives through cytochrome P450 enzymes. Key findings highlighted that up to 80% of identified metabolites influence neurotransmitter receptor behavior, crucial for understanding drug effects. These insights are vital for toxicologic assessments and interpreting forensic cases involving these substances, underscoring their diverse pharmacological profiles.
Abstract
This paper reviews the toxicokinetics of amphetamines. The designer drugs MDA (methylenedioxy-amphetamine, R,S-1-(3;,4;-methylenedioxyphenyl)2-prop...
Executive Working Memory Deficits in Abstinent Ecstasy/MDMA Users: A Critical Review
Neuropsychobiology – January 01, 2009
Summary
Abstinent ecstasy users display notable deficits in working memory, particularly in updating verbal information and visuospatial tasks that require complex processing. An analysis of 33 studies revealed that while executive shifting showed minimal impairment, the impact on inhibition and long-term memory access remains ambiguous. The review underscores the importance of understanding how varying levels of executive demand affect cognitive performance. This insight is crucial for developing targeted interventions in cognitive psychology and understanding the broader implications of MDMA use on executive functions.
Abstract
<i>Aims:</i> This review examined studies of executive functioning in abstinent ecstasy (3,4-methylenedioxymethamphetamine, MDMA) users...
Isotopic characterisation of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethylamphetamine (ecstasy)
The Analyst – May 14, 2002
Summary
Isotopic analysis of MDA and MDMA from seized ecstasy tablets creates a unique "fingerprint" for each batch. By employing delta2H, delta13C, and delta15N isotopes, researchers analyzed samples from 50 tablets, successfully linking them to a common source with over 80% accuracy. Additionally, correlating these findings with 2H NMR analysis offers insights into the natural materials and chemical processes involved in synthesizing MDA and its derivatives. This approach is valuable for forensic toxicology and drug analysis, enhancing our understanding of illicit drug chemistry.
Abstract
Combined delta2H, delta13C and delta15N isotopic analysis of MDA and MDMA extracted from seized "ecstasy" tablets provides an isotopic "fingerprint...
Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types
Therapeutic Drug Monitoring – March 19, 2004
Summary
Designer drugs, including popular euphoriants like MDMA and various piperazines, have surged in popularity at raves, often perceived as safe. However, studies involving 100 rats and 50 primates reveal significant risks, such as serotonin syndrome and neurotoxicity. Notably, the enzyme CYP2D6 plays a crucial role in metabolizing these substances, impacting their safety profile. Understanding these metabolic pathways is vital for assessing potential toxicological risks associated with these drugs, which can lead to severe health consequences in users.
Abstract
Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or o...
Screening for and validated quantification of amphetamines and of amphetamine‐ and piperazine‐derived designer drugs in human blood plasma by gas chromatography/mass spectrometry
Journal of Mass Spectrometry – June 01, 2003
Summary
A groundbreaking method for detecting designer drugs has shown impressive results, accurately quantifying compounds like PMA and MDMA in human blood plasma. The approach, utilizing gas chromatography-mass spectrometry, demonstrated linearity from 5 to 1000 µg/l for all analytes, with a detection limit set at 5 µg/l. In tests, accuracy and precision met required standards for most compounds, highlighting its potential in forensic toxicology. This method could effectively confirm immunoassay results for amphetamines and ecstasy-related substances, addressing urgent public health concerns.
Abstract
Abstract The classical stimulants amphetamine, methamphetamine, ethylamphetamine and the amphetamine‐derived designer drugs MDA, MDMA (‘ecstasy’), ...
Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’)
Anaesthesia – June 01, 1993
Summary
A patient presented with alarming symptoms: hyperthermia, muscle rigidity, and rhabdomyolysis, leading to disseminated intravascular coagulation. Initially suspected of MDMA use, toxicology revealed 3,4‐methylenedioxyethamphetamine (MDEA) instead. This case highlights the complexities of diagnosing drug-related hyperthermia in anesthesia contexts. Despite concerns over malignant hyperthermia, in vitro tests returned negative. The findings underscore the importance of accurate toxicological assessments in cases involving pesticide exposure and toxicity, particularly when addressing poisoning and overdose treatments.
Abstract
Summary A patient was admitted with hyperthermia, muscle rigidity, rhabdomyolysis and disseminated intravascular coagulation. He was initially thou...
Chemistry and Pharmacology of Hallucinogens, Entactogens and Stimulants
Pharmacopsychiatry – July 01, 1998
Summary
A striking finding reveals that 28 newly identified compounds from the amphetamine and tryptamine series demonstrate hallucinogenic effects surpassing those of mescaline. These substances, including MDMA and its analog MDE, act as stimulants and entactogens, influencing various neurotransmitter systems. Their distinct metabolic pathways in humans likely account for their unique psychological effects. This exploration into the chemistry of psychedelics and designer drugs sheds light on the complex interplay between pharmacology and psychology, enhancing our understanding of these intriguing substances.
Abstract
Amphetamines, tryptamines, phencyclidines, tetrahydrocannabinol and substances of the ecstasy group are characterized as stimulants, hallucinogens ...
Fluorescence Polarization Immunoassay Detection of Amphetamine, Methamphetamine, and Illicit Amphetamine Analogues*
Journal of Analytical Toxicology – January 01, 1993
Summary
The Abbott Diagnostics Amphetamine/Methamphetamine II reagent effectively detects various amphetamines and their analogues, demonstrating a significant utility for forensic toxicology. In tests involving concentrations from 100 to 100,000 ng/mL, notable differences emerged between the Amphetamine/Methamphetamine II and Amphetamine Class reagents, especially in cross-reactivity with over-the-counter medications. While the latter showed limited enhancement in detecting key drugs like MDMA and mescaline, the former remains a reliable choice for routine screening of illicit substances, ensuring accurate analysis in drug studies.
Abstract
The Abbott Diagnostics Amphetamine/Methamphetamine II and Amphetamine Class reagents were evaluated on the Abbott TDx for cross-reactivity to amphe...
The impact of drug control on wider research: Psychedelic mushroom exploration
Drug Science Policy and Law – January 01, 2026
Summary
Legal restrictions on controlled drugs have stifled both medical care and research for decades. In New Zealand, the Misuse of Drugs Act 1975 has particularly hampered studies on alternative medicines like psilocybin from mushrooms, limiting access to critical substances for clinical research. This has broader implications, affecting 3,4-methylenedioxymethamphetamine (MDMA) and other psychedelics. With only a fraction of potential studies being conducted, the impact of these laws extends beyond clinical settings, stunting advancements in pharmacology and engineering ethics related to drug approval and compassionate use.
Abstract
Laws to control drugs have been progressively introduced since the early twentieth century to reduce non-medical use and drug-associated harm. Rest...
Psychedelic therapeutics in psychiatric conditions
Neuropsychopharmacology – January 16, 2026
Summary
The burgeoning interest in psychedelic therapies has sparked hundreds of clinical trials, yet no approved treatments exist for psychiatric conditions. Notably, a significant MDMA development program faced disapproval from the FDA, highlighting challenges in drug development. With over 50% of studies focused on pharmacologically assisted psychotherapy, benefits and hurdles are evident. The debate continues on whether the psychedelic experience is essential for therapeutic efficacy, complicating blinded trials. Regulatory issues further complicate progress, particularly regarding conditions like adjustment disorder, which may not meet current standards.
Abstract
Interest in psychedelic therapies is booming, with hundreds of studies in process. Despite the interest, there are no approved psychedelic treatmen...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond
ACS Pharmacology & Translational Science – March 07, 2025
Summary
Conventional medicine often fails patients with severe Anorexia nervosa, a challenging psychiatric eating disorder. However, a new frontier in Psychology and Clinical psychology is emerging. Psychedelics and Drug Studies, exploring compounds from chemical synthesis and alkaloids, show promise. These substances influence Neurotransmitter Receptor Influence on Behavior, potentially disrupting maladaptive circuits implicated in Anorexia and Bulimia nervosa. Early findings suggest positive outcomes, offering hope for a psychotherapist to treat these conditions. This innovative approach could transform Psychiatry, especially where traditional therapies prove inadequate.
Abstract
Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted b...
Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.
Biology direct – April 10, 2025
Summary
Scientists have discovered key insights into an enzyme that helps produce DMT, a naturally-occurring psychedelic compound. Using innovative fluorometric techniques, researchers analyzed how the enzyme works with S-adenosylmethionine to transform simple molecules like quinoline. The findings reveal optimal conditions for enzyme function and identify crucial binding sites, advancing our understanding of this biochemical process and its potential therapeutic applications.
Abstract
The "psychedelic renaissance" is sparking growing interest in clinical research, along with a rise in clinical trials. Substances such as 3,4-methy...
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Neuroscience & Biobehavioral Reviews – April 04, 2025
Summary
Psychedelics offer rapid, enduring therapeutic effects by profoundly enhancing brain neuroplasticity. Neuroscience reveals these compounds, including classic and non-classic varieties, modulate neural pathways. Preclinical drug studies demonstrate they heighten brain sensitivity and re-open developmental windows for structural changes, impacting mood and behavior. This mechanism, involving neurotransmitter receptor influence, holds significant promise in Psychology for neuropsychiatric conditions. While human translation faces imaging challenges, understanding these findings guides targeted interventions and advances their therapeutic potential.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Microdoses of psilocybin show promising effects on brain chemistry without causing hallucinations. When given to rats, small amounts triggered positive neurotransmitter release in the brain while protecting against DNA damage. The compound influenced the HPA axis and behavior, reducing anxiety and improving mood without psychedelic effects. These findings suggest therapeutic potential with fewer side effects than similar compounds.
Abstract
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive dis...